CG Oncology Study ID:
Cretostimogene grenadenorepvec (CG0070)

Non-Muscle Invasive Bladder Cancer



A Study of Intravesical CG0070 for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

The BOND-003
study is testing an investigational drug called cretostimogene grenadenorepvec (CG0070) for adults with non-muscle invasive bladder cancer (NMIBC) who have already tried BCG treatment. Cretostimogene grenadenorepvec (CG0070) is a type of immunotherapy, which is different from chemotherapy. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.

In this study,
Cretostimogene grenadenorepvec (CG0070) will be given intravesically, meaning it is put directly into the bladder using a catheter (a thin tube put into your bladder). Throughout the study doctors will monitor your health and how your cancer is responding to the treatment.

Patient Eligibility

Study Site Locations

Contact Us